Immunic, Inc. (NASDAQ:IMUX – Get Free Report) saw a large growth in short interest in the month of October. As of October 15th, there was short interest totalling 3,470,000 shares, a growth of 29.5% from the September 30th total of 2,680,000 shares. Based on an average daily trading volume, of 576,100 shares, the short-interest ratio is currently 6.0 days.
Analyst Ratings Changes
A number of research analysts have issued reports on the company. Leerink Partnrs raised Immunic to a “strong-buy” rating in a research note on Monday, September 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $28.00 price target on shares of Immunic in a research note on Tuesday, July 16th. Leerink Partners reiterated an “outperform” rating and issued a $5.00 price target on shares of Immunic in a report on Monday, September 9th. B. Riley initiated coverage on shares of Immunic in a research report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, StockNews.com raised Immunic from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $11.20.
Check Out Our Latest Analysis on IMUX
Institutional Trading of Immunic
Immunic Price Performance
Immunic stock opened at $1.31 on Wednesday. The firm has a 50-day moving average of $1.51 and a 200-day moving average of $1.36. The company has a market cap of $118.00 million, a price-to-earnings ratio of -0.87 and a beta of 1.84. Immunic has a one year low of $0.95 and a one year high of $2.11.
Immunic (NASDAQ:IMUX – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. During the same period in the prior year, the company earned ($0.54) earnings per share. As a group, sell-side analysts expect that Immunic will post -0.93 earnings per share for the current year.
About Immunic
Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
See Also
- Five stocks we like better than Immunic
- What is Insider Trading? What You Can Learn from Insider Trading
- Oklo Stock: Nuclear Powerhouse or Radioactive Hype?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- QuantumScape: Solid State EV Batteries Nearing Commercialization
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.